8-KMaterial AgreementsShareholder MattersCorporate Changes+2

Cencora, Inc. 8-K Report, Material Agreement (Nov 12, 2009)

Filed November 12, 2009For Securities:COR

Summary

Cencora, Inc. (formerly AmerisourceBergen Corporation) filed an 8-K on November 12, 2009, primarily announcing the acceleration of the expiration date for its shareholder rights plan. The rights, originally set to expire in August 2011, will now expire on November 20, 2009. This action effectively unwinds a previous poison pill provision intended to protect against hostile takeovers, signaling a potential shift in the company's strategy or risk assessment regarding unsolicited acquisition interest. In conjunction with the shareholder rights plan amendment, the company also announced positive shareholder-friendly actions. These include a significant 33% increase in its quarterly dividend, raising it from $0.06 to $0.08 per common share. Furthermore, the Board of Directors authorized a new $500 million share repurchase program, demonstrating confidence in the company's valuation and commitment to returning capital to shareholders. Investors should note the potential implications of these actions on corporate governance and capital allocation.

Key Highlights

  • 1Shareholder rights plan (poison pill) set to expire significantly earlier, on November 20, 2009.
  • 2Quarterly dividend increased by 33%, from $0.06 to $0.08 per common share.
  • 3New $500 million share repurchase program authorized, effective immediately.
  • 4The amendment to the Rights Agreement was entered into on November 12, 2009, and the rights will expire on November 20, 2009.
  • 5Company to file a Certificate of Elimination for Series A Preferred Stock upon the expiration of the rights.
  • 6A new risk factor is disclosed concerning potential adverse effects from qui tam litigation, specifically a pending case involving Amgen and allegations of conspiracy related to drug sales and claims submission.
  • 7The company is cooperating with a subpoena from the U.S. Attorney's Office related to the qui tam litigation.

Frequently Asked Questions

The acceleration of the shareholder rights agreement's expiration, from August 2011 to November 20, 2009, effectively unwinds the 'poison pill' provision. While the specific strategic reasons are not detailed, this action typically signals that the board no longer sees a significant immediate threat of a hostile takeover or may be adopting a different approach to corporate governance and shareholder value.

The substantial 33% increase in the quarterly dividend and the authorization of a new $500 million share repurchase program are positive signals to investors. They indicate management's confidence in the company's financial health and future prospects, and a commitment to returning capital to shareholders through increased income and potentially boosting earnings per share through buybacks.

The company disclosed a new risk factor related to 'qui tam litigation,' specifically a pending case where Cencora's subsidiaries are accused of conspiring with Amgen to promote a drug and causing providers to submit false claims. If found liable, or if government authorities intervene and find violations, the company could face significant financial damages, penalties, and potential exclusion from federal and state health programs, which could adversely affect its business and results of operations.

Upon the expiration of the rights on November 20, 2009, Cencora will file a Certificate of Elimination with the Secretary of State of Delaware. This action will eliminate the Certificate of Designations for the company's Series A Preferred Stock, which was previously issuable under certain circumstances upon the exercise of the rights. This effectively removes a potential class of preferred stock from the company's capital structure.